<DOC>
	<DOC>NCT01097655</DOC>
	<brief_summary>Usage, dosing, tolerability, and effectiveness of Kaletra tablets in Human Immunodeficiency Virus-infected patients.</brief_summary>
	<brief_title>Study on the Usage, Dosing, Tolerability, and Effectiveness of Kaletra Tablet</brief_title>
	<detailed_description>The objective of this study is to observe and collect data on the usage, dosing, tolerability, and effectiveness of Kaletra tablet. In some patients the study is to show the impact of changing therapy to Kaletra tablet from other regimens on tolerability.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<criteria>Patients with Human Immunodeficiency Virus infection Patients that will be treated with KALETRA tablets, independent from their participation in this study Hypersensitivity against Kaletra or other ingredients Severe liver insufficiency No concommitant astemizole, terfenadine, oral midazolam, triazolam, cisapride, pimozide, amiodarone, ergotamine, dihydroergotamine, ergometrine, methylergometrine, vardenafil and St. John's wort Patients that received more than 1 protease inhibitor during their therapy history are excluded</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Viral load</keyword>
	<keyword>Human immunodeficiency Virus</keyword>
	<keyword>Effectiveness</keyword>
	<keyword>Treatment-na√Øve</keyword>
	<keyword>Tablets</keyword>
	<keyword>Infection</keyword>
	<keyword>Non Nucleoside Reverse Transcriptase Inhibitor</keyword>
</DOC>